Invitae
Invitae Sues Natera Alleging Infringement of Patent on DNA Sequencing Assembly Technique
Invitae believes its '799 patent improves upon prior art and wants a US District Court to find that Natera is infringing its IP with its Signatera test.
Invitae Q1 Revenues Increase 61 Percent
The company reported revenues of $103.6 million, exceeding the consensus Wall Street estimate.
Invitae, PCT Therapeutics, Genome Medical Partner to Offer Genetic Testing for Cerebral Palsy
The testing program will be available for patients in the US who have symptoms or a diagnosis of cerebral palsy but no evidence of brain injury.
Invitae to Provide Genetic Testing Within eMERGE Population Screening Study
As a new clinical affiliate, Invitae will test up to 25,000 patients in a study exploring the role of genetics in cancer, heart disease, and other conditions.
Invitae Acquiring Genosity for $200M; Investment Group Provides Firm $1.15B in Senior Notes
Invitae expects that Genosity's software and data management platform will allow it to quickly advance several oncology tests in development.
Feb 17, 2021
Invitae Q4 2020 Revenues Increase 51 Percent
Feb 1, 2021
Oppenheimer Downgrades Invitae to Perform Rating
Jan 22, 2021
Invitae Prices $400M Common Stock Offering
Jan 20, 2021
Invitae to Raise $400M in Proposed Public Offering
Jan 11, 2021
Invitae 2020 Preliminary Revenues Rise 28 Percent
Dec 28, 2020
Nov 5, 2020
Invitae Q3 Revenues Increase 22 Percent
Oct 14, 2020